Table 2. The association of Clinicopathologic characteristics of 110 ESCC patients’ with HDAC8 and CDKN2A expression in FFPE cancerous tissues.
| Variables | All cases | HDAC8 expression (% within total cases) | CDKN2A expression (% within total cases) | |||||
|---|---|---|---|---|---|---|---|---|
| Weak or no | High | P* | Weak or no | High | P* | |||
| Age (years) | ||||||||
| <65 | 49 | 7 (6.4) | 42 (38.2) | 0.5 | 37 (33.6) | 12 (10.9) | 0.3 | |
| >65 | 61 | 9 (8.2) | 52 (47.3) | 51 (46.4) | 10 (9.1) | |||
| Gender | ||||||||
| Male | 40 | 4 (3.6) | 36 (32.7) | 0.4 | 36 (32.7) | 4 (3.6) | 0.05 | |
| Female | 70 | 12 (10.9) | 58 (52.7) | 52 (47.3) | 18 (16.4) | |||
| Smoking | ||||||||
| Smoker | 64 | 12 (10.9) | 52 (47.3) | 0.1 | 50 (45.5) | 14 (12.7) | 0.6 | |
| Non-smoker | 46 | 4 (3.6) | 42 (38.2) | 38 (34.5) | 8 (7.3) | |||
| Drinking habit | ||||||||
| Alcoholic | 56 | 11 (10.0) | 45 (40.9) | 0.1 | 41 (37.3) | 15 (13.6) | 0.09 | |
| Non-alcoholic | 54 | 5 (4.5) | 49 (44.5) | 47 (42.7) | 7 (6.4) | |||
| Tumor stages | ||||||||
| T1 | 12 | 1 (0.9) | 11 (10.0) | 6 (5.5) | 6 (5.5) | |||
| T2 | 43 | 5 (4.5) | 38 (34.5) | 0.6 | 36 (32.7) | 7 (6.4) | 0.01 | |
| T3 | 35 | 7 (6.4) | 28 (25.5) | 27 (24.5) | 8 (7.3) | |||
| T4 | 20 | 3 (2.7) | 17 (15.5) | 19 (17.3) | 1 (0.9) | |||
| Nodal station | ||||||||
| N0 | 44 | 9 (8.2) | 35 (31.8) | 31 (28.2) | 13 (11.8) | |||
| N1 | 24 | 4 (3.6) | 20 (18.2) | 0.05 | 17 (15.5) | 7 (6.4) | 0.003 | |
| N2 | 29 | 3 (2.7) | 26 (23.6) | 27 (24.5) | 2 (1.8) | |||
| N3 | 13 | 0 (0.0) | 13 (11.8) | 13 (11.8) | 0 (0.0) | |||
| Differentiation | ||||||||
| Poor | 47 | 8 (7.3) | 39 (35.5) | 36 (32.7) | 11 (10.0) | |||
| Moderate | 31 | 4 (3.6) | 27 (24.5) | 0.8 | 26 (23.6) | 5 (4.5) | 0.7 | |
| Well | 32 | 4 (3.6) | 28 (25.5) | 26 (23.6) | 6 (5.5) | |||
| Survival | ||||||||
| Alive | 50 | 14 (12.7) | 36 (32.7) | 0.001 | 29 (26.4) | 21 (19.1) | 0.001 | |
| Dead | 60 | 2 (1.8) | 58 (52.7) | 59 (53.6) | 1 (0.9) | |||
| Progression of disease | ||||||||
| Progression | 69 | 2 (1.8) | 67 (60.9) | 68 (61.8) | 1 (0.9) | |||
| No progression | 41 | 14 (12.7) | 27 (24.5) | 0.001 | 20 (18.2) | 21 (19.1) | 0.001 | |
*, Chi-square test. FFPE, formalin-fixed paraffin-embedded.